Translational Development Acquisition Corp.
TDAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $1,065,788 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $320,869 | $0 | $0 |
| Gross Profit | $744,919 | $0 | $0 |
| % Margin | 69.9% | – | – |
| R&D Expenses | $0 | $0 | $0 |
| G&A Expenses | $9,125,378 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 |
| % Margin | -0% | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 |
| % Margin | -0% | – | – |
| EPS | -0.016 | -0.12 | -0.017 |
| % Growth | 86.5% | -589.7% | – |
| EPS Diluted | -0.016 | -0.12 | -0.017 |
| Weighted Avg Shares Out | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $508,563 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 |
| % Margin | -0% | – | – |